Traws Pharma, INC 8-K filings

Traws Pharma reports positive data supporting tivoxavir marboxil as a single-dose therapeutic agent for bird flu, ongoing FDA interaction for potential accelerated approval, and a cash runway into Q1 2026.

Traws Pharma announces the retirement of CEO Werner Cautreels, with Iain Dukes stepping in as Interim CEO, effective upon the filing of the company's 2024 Annual Report.

Traws Pharma's ratutrelvir, a novel COVID-19 treatment, shows promising Phase 1 data, suggesting it can be used without ritonavir and may reduce the likelihood of COVID rebound.

Traws Pharma reports positive preclinical results for its single-dose antiviral, tivoxavir marboxil (TXM), in treating bird flu in non-human primates.

Traws Pharma announces positive data presented at ICAR 2025 for tivoxavir marboxil (TXM), an investigational one-dose influenza therapy, demonstrating potential for the treatment of H5N1 avian influenza.

Traws Pharma, Inc. has entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC to sell up to $50 million of its common stock.

Traws Pharma reports positive topline data from a preclinical study showing its antiviral candidate, tivoxavir marboxil, effectively suppressed disease in ferrets infected with H5N1 bird flu.

Traws Pharma announces it has regained compliance with Nasdaq's minimum stockholders' equity requirement, ensuring continued listing on the NASDAQ Capital Market.

Traws Pharma modifies its Series A Warrants, altering the change of control threshold and refining the Black Scholes valuation method for fundamental transactions.

Traws Pharma stockholders approved proposals related to the issuance of common stock upon warrant exercises at a special meeting held on February 17, 2025.

Traws Pharma believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent offering, but confirmation from Nasdaq is still pending.

Traws Pharma, Inc. announces the resignation of Chief Financial Officer Mark Guerin, effective immediately, and the appointment of Nora Brennan as Interim Chief Financial Officer.

Traws Pharma has announced the successful completion of Phase 1 clinical studies for its investigational single-dose oral therapy, tivoxavir marboxil, aimed at treating and preventing H5N1 avian influenza.

Traws Pharma has announced a financing agreement to raise up to $72.6 million to accelerate the development of its antiviral treatment for bird flu.

Luba Greenwood has resigned from the Board of Directors of Traws Pharma, Inc., effective December 16, 2024.

Traws Pharma is at risk of being delisted from the Nasdaq Capital Market due to failing to meet the minimum stockholders' equity requirement, despite regaining compliance with the minimum bid price rule.

Traws Pharma reports promising Phase 1 data for its COVID and flu antiviral candidates, alongside its Q3 2024 financial results showing increased R&D spending and a net loss.

Traws Pharma has regained compliance with Nasdaq's minimum bid price requirement but still faces challenges regarding minimum stockholders' equity.

Traws Pharma has received a delisting notice from Nasdaq after failing to maintain a minimum share price of $1.00, and intends to request a hearing to present a plan to regain compliance.

Traws Pharma has completed a 1-for-25 reverse stock split and increased its authorized shares of common stock, effective September 20, 2024.

Traws Pharma has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, placing its listing status at risk.

Traws Pharma reported its Q2 2024 financial results, highlighting a merger with Trawsfynydd Therapeutics, a $14 million private placement, and progress in its clinical programs.

Traws Pharma has engaged KPMG as its new independent registered public accounting firm, replacing Ernst & Young, effective for the year ending December 31, 2024.

Traws Pharma has amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of outstanding shares.

Traws Pharma's President and Chief Scientific Officer, Steven M. Fruchtman, has resigned, triggering a dispute over severance payments.

Traws Pharma, formerly Onconova Therapeutics, has filed an amended 8-K report including audited financials of Trawsfynydd Therapeutics and pro forma financial information following their merger.

Traws Pharma has announced that Ernst & Young will not be standing for reappointment as their auditor for the fiscal year ending December 31, 2024.

Traws Pharma reported its first quarter 2024 financial results, highlighted by a $14 million capital raise and progress in its clinical pipeline.

Traws Pharma presented an investor update highlighting its pipeline of potential best-in-class product candidates for cancer and respiratory viral diseases.

Onconova Therapeutics and Trawsfynydd Therapeutics have merged to create Traws Pharma, a company focused on developing treatments for viral and oncological diseases, supported by a $14 million private placement.